Literature DB >> 2522344

Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

M Awwad1, R J North.   

Abstract

It was shown that it is possible to use cyclophosphamide (Cy) to cause immunologically mediated regression of the immunogenic, Cy-resistant L5178Y lymphoma in syngeneic and semisyngeneic mice. In order to cause tumor regression it was necessary to give Cy shortly before or shortly after tumor implantation. However, regardless of whether Cy was given before or after tumor implantation, tumor regression did not commence until 10 days of progressive tumor growth, by which time the tumor was 1 cm in diameter. Tumor regression was associated with the presence in the spleen of an increased number of Lyt-2+ T-cells capable of passively transferring immunity to tumor-bearing recipients. This augmented level of immunity was sustained throughout the period of tumor regression. In contrast, a lower level of concomitant immunity generated by control tumor bearers decayed after Day 12 of tumor growth. Because the therapeutic effect of Cy could be inhibited by passive transfer of L3T4+ T-cells from normal donor mice it is apparent that the therapeutic effect of Cy is based on its ability to preferentially destroy L3T4+ suppressor T-cells. These putative precursor suppressor T-cells were regenerated 4 days after being destroyed by Cy. Taken together the results represent a striking example of the negative regulatory influence of suppressor T-cells on the immune response to an immunogenic tumor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522344

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Reduced numbers of CD4+ suppressor cells with subsequent expansion of CD8+ protective T cells as an explanation for the paradoxical state of enhanced resistance to Leishmania in T-cell deficient BALB/c mice.

Authors:  J O Hill
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

3.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

Authors:  K Staveley-O'Carroll; E Sotomayor; J Montgomery; I Borrello; L Hwang; S Fein; D Pardoll; H Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 4.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

Authors:  Paul Andrew Antony; Nicholas P Restifo
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

5.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Authors:  E D Kwon; B A Foster; A A Hurwitz; C Madias; J P Allison; N M Greenberg; M B Burg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 6.  CD25+ CD4+ regulatory T-cells in cancer.

Authors:  David C Linehan; Peter S Goedegebuure
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

8.  Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.

Authors:  Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Sanne de Jong; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans
Journal:  J Biomed Biotechnol       Date:  2010-05-23

9.  Comparative methodologies of regulatory T cell depletion in a murine melanoma model.

Authors:  Norimasa Matsushita; Shari A Pilon-Thomas; Lisa M Martin; Adam I Riker
Journal:  J Immunol Methods       Date:  2008-02-13       Impact factor: 2.303

10.  Cyclophosphamide treatment antagonizes the in vitro development of Mycobacterium lepraemurium-induced suppressor cell precursors.

Authors:  D Gosselin; R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.